Delivering on the promise of precision medicine, Loxo Oncology Inc.'s larotrectinib could be the first of a modern form of oncology drug development – facilitated by US FDA's breakthrough designation program.
Larotrectinib is a targeted therapy that selectively inhibits the tropomyosin receptor kinase (TRK) fusion protein and is one of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?